Physician profile
Prashanth Ashok Kumar
NPI 1245726371
$269.42
in general payments reported to CMS, 2019-2025
7 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $61.58 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244 · Education: $25.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.62 |
| Education | $25.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $72.97 | 2025 | |
| Merck Sharp & Dohme LLC | $57.41 | 2025 | Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $41.98 | 2024-2025 | Enhertu, Injectafer |
| Coherus Oncology, INC. | $30.96 | 2025 | Udenyca |
| Alexion Pharmaceuticals, INC. | $24.28 | 2024 | Ultomiris |
| Penumbra, INC. | $21.12 | 2024 | Indigo System |
| Genentech USA, INC. | $20.70 | 2025 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Ashok Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.